Integrin inhibitors and their methods of use

   
   

The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a .alpha..sub.v.beta..sub.3, .alpha..sub.v.beta..sub.5, .alpha..sub.v.beta..sub.6, .alpha..sub.5.beta..sub.1 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

La invención abarca los compuestos de la novela que son eficaces en la profilaxis y el tratamiento de enfermedades, tales como enfermedades mediadas los receptores del integrin, en detalle, enfermedades o condiciones mediadas por los receptores del integrin, tales como un alpha..sub.v.beta..sub.3, alpha..sub.v.beta..sub.5, alpha..sub.v.beta..sub.6, alpha..sub.5.beta..sub.1 y similares. La invención abarca los compuestos de la novela, farmacéutico sales aceptables de eso, composiciones y métodos farmacéuticos para la profilaxis y el tratamiento de tales enfermedades y desórdenes. La invención sujeta también se relaciona con los procesos para hacer compuestos tan bien como a los intermedios útiles en tales procesos.

 
Web www.patentalert.com

< Methods and compositions for treating IgE-related disease using NNT-1 inhibitors

< Antibodies to the metalloproteinase inhibitor

> Apoptosis-inducing factor

> Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI

~ 00158